

Review: venlafaxine may be effective for fibromyalgia Tx

January 16 2015



(HealthDay)—Venlafaxine seems to be effective for the treatment of fibromyalgia, although studies are limited by small sample size and methodological concerns, according to a review published in the February issue of the *Journal of Clinical Pharmacy and Therapeutics*.

Luke A. VanderWeide, Pharm.D., from the University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences in Aurora, and colleagues conducted a <u>systematic review</u> of venlafaxine for the treatment of <u>fibromyalgia</u>. The authors included data from five clinical studies (four open-label cohort studies and one randomized controlled trial) that investigated venlafaxine for the treatment of fibromyalgia. They then graded the studies according to the strength of evidence.



The researchers found that four of the published studies reported improvement in at least one outcome. There were generally consistent improvements in outcome measures related to pain, including the Fibromyalgia Impact Questionnaire, Visual Analog Scale, McGill Pain Questionnaire, and Clinical Global Impression scale. The studies were limited by small sample size, inconsistency of outcomes, and methodological concerns.

"Studies assessing the efficacy of venlafaxine in the treatment of fibromyalgia to date have been limited by small sample size, inconsistent venlafaxine dosing, lack of placebo control, and lack of blinding," the authors write. "In the context of these limitations, venlafaxine appears to be at least modestly effective in treating fibromyalgia."

More information: Abstract

Full Text

Copyright © 2015 HealthDay. All rights reserved.

Citation: Review: venlafaxine may be effective for fibromyalgia Tx (2015, January 16) retrieved 1 May 2024 from

https://medicalxpress.com/news/2015-01-venlafaxine-effective-fibromyalgia-tx.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.